NCT04756765View on ClinicalTrials.gov

Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 23, 2023

Primary Completion Date

December 18, 2024

Study Completion Date

December 18, 2024

Conditions
Breast CancerAdvanced Breast Cancer
Interventions
DRUG

Talazoparib Tosylate

Talazoparib1 mg/day is to be administered orally on a continuous dosing schedule.

Trial Locations (1)

94305

Stanford University, Stanford

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Stanford University

OTHER